Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048).

Blood
Shinichi KitadaJ C Reed

Abstract

Altered expression of Bcl-2 family proteins plays central roles in apoptosis dysregulation in cancer and leukemia, promoting malignant cell expansion and contributing to chemoresistance. In this study, we compared the toxicity and efficacy in mice of natural product gossypol and its semisynthetic derivative apo-gossypol, compounds that bind and inhibit antiapoptotic Bcl-2 family proteins. Daily oral dosing studies showed that mice tolerate doses of apogossypol 2- to 4-times higher than gossypol. Hepatotoxicity and gastrointestinal toxicity represented the major adverse activities of gossypol, with apogossypol far less toxic. Efficacy was tested in transgenic mice in which Bcl-2 is overexpressed in B cells, resembling low-grade follicular lymphoma in humans. In vitro, Bcl-2-expressing B cells from transgenic mice were more sensitive to cytotoxicity induced by apogossypol than gossypol, with LD50 values of 3 to 5 microM and 7.5 to 10 microM, respectively. In vivo, using the maximum tolerated dose of gossypol for sequential daily dosing, apogossypol displayed superior activity to gossypol in terms of reducing splenomegaly and reducing B-cell counts in spleens of Bcl-2-transgenic mice. Taken together, these studies indicate that ap...Continue Reading

References

Dec 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M KatsumataJ C Reed
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J C ReedT Miyashita
Jan 1, 1996·Cancer Treatment and Research·J C ReedH Kobayashi
Jul 29, 1998·Journal of Neurochemistry·A HochmanD Offen
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·H H LeeG Cheng
Oct 25, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J M ZapataJ C Reed
Apr 5, 2001·Journal of Applied Toxicology : JAT·B Ballantyne, T J Cawley
Mar 29, 2002·Journal of Applied Toxicology : JAT·J K Miller, D E Lenz
Nov 25, 2003·Oncogene·Suzanne CoryJerry M Adams
Nov 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Juan M ZapataJohn C Reed
Sep 17, 2005·Proceedings of the National Academy of Sciences of the United States of America·Amelia CimminoCarlo M Croce
Apr 29, 2006·Cell Death and Differentiation·D ZhaiJ C Reed
Jul 25, 2006·Journal of Pharmaceutical and Biomedical Analysis·L CowardL Jia
Oct 10, 2006·Oncogene·G A Calin, C M Croce
Oct 25, 2006·Nature Reviews. Cancer·George A Calin, Carlo M Croce
Feb 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan O'BrienKanti R Rai

❮ Previous
Next ❯

Citations

Aug 3, 2013·Investigational New Drugs·Kumudha Balakrishnan, Varsha Gandhi
May 2, 2009·Pharmaceutical Research·Mei Lan TanTengku Sifzizul Tengku Muhammad
Apr 25, 2009·Cell Death and Differentiation·M VoglerG M Cohen
May 15, 2010·Nature Reviews. Drug Discovery·Simone FuldaGuido Kroemer
Oct 29, 2008·Oncogene·K W Yip, J C Reed
Jun 8, 2011·Antioxidants & Redox Signaling·Simone Fulda, Guido Kroemer
Jan 23, 2013·The Cancer Journal·Robert R ZielinskiKim N Chi
Jun 11, 2009·Molecular Cancer Therapeutics·Nidhish SasiBo Lu
Apr 18, 2009·Molecular Cancer Therapeutics·Jun WeiMaurizio Pellecchia
Jun 11, 2009·Molecular Cancer Therapeutics·Dmitri V RozanovAlex Y Strongin
Sep 9, 2011·Genes & Cancer·Rana ElkholiJerry E Chipuk
Jan 18, 2011·Hematology·John P Leonard, Peter Martin
May 27, 2008·Blood·Jonathan W Friedberg
Dec 25, 2009·Journal of Hematology & Oncology·Nishant TagejaRamzi M Mohammad
Jun 20, 2012·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Xiaoge NiuSenming Wang
Dec 4, 2013·Leukemia & Lymphoma·Shadia ZamanVarsha Gandhi
Jan 24, 2013·Leukemia & Lymphoma·Mary Ann AndersonAndrew W Roberts
Dec 27, 2011·Expert Opinion on Therapeutic Patents·Naval BajwaZaneta Nikolovska-Coleska
Aug 20, 2011·Expert Opinion on Investigational Drugs·Bridget A QuinnPaul B Fisher
Mar 25, 2015·Artificial Cells, Nanomedicine, and Biotechnology·Hitesh JaganiVenkata Rao Josyula
Feb 13, 2015·Molecular Medicine Reports·Wenhua ZhanXiaofeng Huang
Mar 1, 2012·Drug Discovery Today. Therapeutic Strategies·Tudor I OpreaLarry A Sklar
Jul 6, 2010·Mitochondrion·Lucia BiasuttoJiri Neuzil
Oct 29, 2008·Hematology/oncology Clinics of North America·Luca PaoluzziOwen A O'Connor
Aug 21, 2008·International Journal of Cancer. Journal International Du Cancer·Zhe-Yu HuYi-Xin Zeng
Jul 22, 2008·Biochemical Pharmacology·Isabel Marzo, Javier Naval
Jan 24, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jingwei ShaoJinling Huang
Aug 9, 2016·Trends in Cell Biology·Mark P A Luna-Vargas, Jerry Edward Chipuk
Nov 3, 2009·Advances in Food and Nutrition Research·Xi WangYueming Jiang
May 27, 2017·Current Medicinal Chemistry·Yun ZengDaocheng Wu
Jul 23, 2016·The FEBS Journal·Divyaanka IyerSathees C Raghavan
Jan 1, 2014·Advances in Medicine·Meike Vogler
Oct 25, 2017·The Biochemical Journal·Astrid Ruefli-Brasse, John C Reed
Mar 27, 2020·Frontiers in Oncology·Maria Andrea DesbatsMonica Montopoli

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.